BB BIOTECH AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.45 CHF | -0.25% |
|
-2.29% | -5.38% |
| Apr. 26 | Switzerland's BB Biotech Swings to Q1 Profit; Operating Income Jumps | MT |
| Apr. 25 | BB Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,670 | 4,108 | 4,274 | 3,027 | 2,345 | 2,219 | - | - |
| Enterprise Value (EV) 1 | 3,790 | 209.4 | 4,626 | 3,389 | 2,649 | 2,510 | 2,543 | 2,219 |
| P/E ratio | 5.42 x | 5.94 x | -10.6 x | -8.49 x | -11.3 x | 14.6 x | 13.6 x | 11.7 x |
| Yield | 5.13% | 4.86% | 4.99% | 5.16% | 4.68% | 5.81% | 5.93% | 6.03% |
| Capitalization / Revenue | 5.04 x | 5.54 x | 1,068,528 x | -9.63 x | -14.1 x | 11.7 x | 22 x | - |
| EV / Revenue | 5.2 x | 0.28 x | 1,156,569 x | -10.8 x | -15.9 x | 13.2 x | 25.3 x | - |
| EV / EBITDA | 5.57 x | 0.3 x | -11.5 x | -9.48 x | -13.2 x | 16 x | 18.9 x | - |
| EV / FCF | 17.6 x | 0.8 x | -48.8 x | 14.7 x | 12.1 x | 13 x | 11 x | - |
| FCF Yield | 5.67% | 125% | -2.05% | 6.82% | 8.24% | 7.71% | 9.12% | - |
| Price to Book | 1.08 x | 1.05 x | 1.3 x | 1.13 x | 1.01 x | 0.95 x | 0.93 x | - |
| Nbr of stocks (in thousands) | 55,400 | 55,400 | 55,400 | 54,846 | 54,846 | 54,846 | - | - |
| Reference price 2 | 66.25 | 74.15 | 77.15 | 55.20 | 42.75 | 40.45 | 40.45 | 40.45 |
| Announcement Date | 2/21/20 | 2/19/21 | 2/18/22 | 2/17/23 | 2/16/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 728.2 | 741.8 | 0.004 | -314.3 | -166.6 | 190 | 100.6 | - |
| EBITDA 1 | 679.9 | 694 | -402.8 | -357.3 | -201.3 | 157.2 | 134.3 | - |
| EBIT 1 | 678.7 | 692.1 | -403.8 | -357.3 | -201.3 | 157.2 | 134.3 | - |
| Operating Margin | 93.21% | 93.31% | -10,093,875% | 113.69% | 120.79% | 82.74% | 133.43% | - |
| Earnings before Tax (EBT) 1 | 677.5 | 691.2 | -404.7 | -357.8 | -206.5 | 151.9 | 58.65 | - |
| Net income 1 | 677.4 | 691.2 | -404.8 | -358 | -206.6 | 151.9 | 72.43 | 190.2 |
| Net margin | 93.03% | 93.18% | -10,120,200% | 113.92% | 124% | 79.95% | 71.97% | - |
| EPS 2 | 12.23 | 12.48 | -7.310 | -6.500 | -3.770 | 2.770 | 2.980 | 3.470 |
| Free Cash Flow 1 | 215 | 262.4 | -94.79 | 231.1 | 218.3 | 193.4 | 231.9 | - |
| FCF margin | 29.53% | 35.38% | -2,369,675% | -73.55% | -131.01% | 101.79% | 230.4% | - |
| FCF Conversion (EBITDA) | 31.62% | 37.82% | - | - | - | 123.03% | 172.67% | - |
| FCF Conversion (Net income) | 31.74% | 37.97% | - | - | - | 127.32% | 320.16% | - |
| Dividend per Share 2 | 3.400 | 3.600 | 3.850 | 2.850 | 2.000 | 2.350 | 2.400 | 2.440 |
| Announcement Date | 2/21/20 | 2/19/21 | 2/18/22 | 2/17/23 | 2/16/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 |
|---|---|---|
| Net sales | - | - |
| EBITDA | - | - |
| EBIT | - | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income 1 | -299.9 | -233.1 |
| Net margin | - | - |
| EPS | -5.430 | - |
| Dividend per Share | - | - |
| Announcement Date | 4/22/22 | 7/22/22 |
1CHF in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 119 | - | 352 | 361 | 304 | 291 | 325 | - |
| Net Cash position 1 | - | 3,898 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 0.1755 x | - | -0.8743 x | -1.011 x | -1.512 x | 1.851 x | 2.416 x | - |
| Free Cash Flow 1 | 215 | 262 | -94.8 | 231 | 218 | 193 | 232 | - |
| ROE (net income / shareholders' equity) | 21.6% | 19% | -11.3% | -12% | -8.25% | 3.7% | 4.1% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 61.30 | 70.30 | 59.30 | 49.00 | 42.40 | 42.80 | 43.40 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 2/21/20 | 2/19/21 | 2/18/22 | 2/17/23 | 2/16/24 | - | - | - |
1CHF in Million2CHF
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
40.45
CHF
Average target price
47.7
CHF
Spread / Average Target
+17.92%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -5.38% | 2.43B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BION Stock
- Financials BB Biotech AG
